Literature DB >> 25953507

Exploiting replicative stress to treat cancer.

Matthias Dobbelstein1, Claus Storgaard Sørensen2.   

Abstract

DNA replication in cancer cells is accompanied by stalling and collapse of the replication fork and signalling in response to DNA damage and/or premature mitosis; these processes are collectively known as 'replicative stress'. Progress is being made to increase our understanding of the mechanisms that govern replicative stress, thus providing ample opportunities to enhance replicative stress for therapeutic purposes. Rather than trying to halt cell cycle progression, cancer therapeutics could aim to increase replicative stress by further loosening the checkpoints that remain available to cancer cells and ultimately inducing the catastrophic failure of proliferative machineries. In this Review, we outline current and future approaches to achieve this, emphasizing the combination of conventional chemotherapy with targeted approaches.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25953507     DOI: 10.1038/nrd4553

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  302 in total

Review 1.  Transcription-replication encounters, consequences and genomic instability.

Authors:  Anne Helmrich; Monica Ballarino; Evgeny Nudler; Laszlo Tora
Journal:  Nat Struct Mol Biol       Date:  2013-04       Impact factor: 15.369

Review 2.  Targeting homologous recombination repair defects in cancer.

Authors:  Bastiaan Evers; Thomas Helleday; Jos Jonkers
Journal:  Trends Pharmacol Sci       Date:  2010-07-02       Impact factor: 14.819

3.  Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation.

Authors:  WooKee Min; Christopher Bruhn; Paulius Grigaravicius; Zhong-Wei Zhou; Fu Li; Anja Krüger; Bénazir Siddeek; Karl-Otto Greulich; Oliver Popp; Chris Meisezahl; Cornelis F Calkhoven; Alexander Bürkle; Xingzhi Xu; Zhao-Qi Wang
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 4.  How dormant origins promote complete genome replication.

Authors:  J Julian Blow; Xin Quan Ge; Dean A Jackson
Journal:  Trends Biochem Sci       Date:  2011-06-07       Impact factor: 13.807

5.  The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair.

Authors:  Claus Storgaard Sørensen; Lasse Tengbjerg Hansen; Jaroslaw Dziegielewski; Randi G Syljuåsen; Cecilia Lundin; Jiri Bartek; Thomas Helleday
Journal:  Nat Cell Biol       Date:  2005-01-23       Impact factor: 28.824

6.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

7.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Authors:  Teresa A Soucy; Peter G Smith; Michael A Milhollen; Allison J Berger; James M Gavin; Sharmila Adhikari; James E Brownell; Kristine E Burke; David P Cardin; Stephen Critchley; Courtney A Cullis; Amanda Doucette; James J Garnsey; Jeffrey L Gaulin; Rachel E Gershman; Anna R Lublinsky; Alice McDonald; Hirotake Mizutani; Usha Narayanan; Edward J Olhava; Stephane Peluso; Mansoureh Rezaei; Michael D Sintchak; Tina Talreja; Michael P Thomas; Tary Traore; Stepan Vyskocil; Gabriel S Weatherhead; Jie Yu; Julie Zhang; Lawrence R Dick; Christopher F Claiborne; Mark Rolfe; Joseph B Bolen; Steven P Langston
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

8.  Cancer phenotypic lethality, exemplified by the non-essential MTH1 enzyme being required for cancer survival.

Authors:  T Helleday
Journal:  Ann Oncol       Date:  2014-04-15       Impact factor: 32.976

9.  An APC/C inhibitor stabilizes cyclin B1 by prematurely terminating ubiquitination.

Authors:  Xing Zeng; Randall W King
Journal:  Nat Chem Biol       Date:  2012-02-26       Impact factor: 15.040

10.  BRCA1 and Tip60 determine the cellular response to ultraviolet irradiation through distinct pathways.

Authors:  Dominique Kranz; Christoph Dohmesen; Matthias Dobbelstein
Journal:  J Cell Biol       Date:  2008-07-14       Impact factor: 10.539

View more
  117 in total

Review 1.  DNA replication stress: from molecular mechanisms to human disease.

Authors:  Sergio Muñoz; Juan Méndez
Journal:  Chromosoma       Date:  2016-01-21       Impact factor: 4.316

2.  Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer.

Authors:  Sejin Chung; Paris Vail; Agnieszka K Witkiewicz; Erik S Knudsen
Journal:  Clin Cancer Res       Date:  2018-12-11       Impact factor: 12.531

3.  Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma.

Authors:  Dhiraj Sikaria; Yaping N Tu; Diana A Fisler; James A Mauro; George Blanck
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-05       Impact factor: 4.553

Review 4.  Proteolytic control of genome integrity at the replication fork.

Authors:  Julie Rageul; Alexandra S Weinheimer; Jennifer J Park; Hyungjin Kim
Journal:  DNA Repair (Amst)       Date:  2019-07-10

5.  PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer.

Authors:  Andrä Brunner; Aldwin Suryo Rahmanto; Henrik Johansson; Marcela Franco; Johanna Viiliäinen; Mohiuddin Gazi; Oliver Frings; Erik Fredlund; Charles Spruck; Janne Lehtiö; Juha K Rantala; Lars-Gunnar Larsson; Olle Sangfelt
Journal:  Elife       Date:  2020-07-06       Impact factor: 8.140

6.  Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).

Authors:  Kristina A Cole; Sharmistha Pal; Rachel A Kudgus; Heba Ijaz; Xiaowei Liu; Charles G Minard; Bruce R Pawel; John M Maris; Daphne A Haas-Kogan; Stephan D Voss; Stacey L Berg; Joel M Reid; Elizabeth Fox; Brenda J Weigel
Journal:  Clin Cancer Res       Date:  2019-12-19       Impact factor: 12.531

7.  Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras.

Authors:  S Haihua Chu; Evelyn J Song; Jonathan R Chabon; Janna Minehart; Chloe N Matovina; Jessica L Makofske; Elizabeth S Frank; Kenneth Ross; Richard P Koche; Zhaohui Feng; Haiming Xu; Andrei Krivtsov; Andre Nussenzweig; Scott A Armstrong
Journal:  Blood Adv       Date:  2018-10-09

8.  ATM/ATR-mediated phosphorylation of PALB2 promotes RAD51 function.

Authors:  Johanna K Ahlskog; Brian D Larsen; Kavya Achanta; Claus S Sørensen
Journal:  EMBO Rep       Date:  2016-04-04       Impact factor: 8.807

9.  Mdm4 supports DNA replication in a p53-independent fashion.

Authors:  Kai Wohlberedt; Ina Klusmann; Polina K Derevyanko; Kester Henningsen; Josephine Ann Mun Yee Choo; Valentina Manzini; Anna Magerhans; Celeste Giansanti; Christine M Eischen; Aart G Jochemsen; Matthias Dobbelstein
Journal:  Oncogene       Date:  2020-05-19       Impact factor: 9.867

10.  Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma.

Authors:  Martin Golkowski; Ho-Tak Lau; Marina Chan; Heidi Kenerson; Venkata Narayana Vidadala; Anna Shoemaker; Dustin J Maly; Raymond S Yeung; Taranjit S Gujral; Shao-En Ong
Journal:  Cell Syst       Date:  2020-08-04       Impact factor: 10.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.